Patent ID: 11959091
Assignee: CELLECTIS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of preparing T-cells for cancer immunotherapy comprising the steps of:
(a) providing primary human T-cells from a donor,
(b) genetically modifying the primary human T-cells to eliminate expression of a gene encoding an immune checkpoint protein, comprising expressing in the cells
(i) a Cas9 endonuclease fused to a nuclear localization signal (NLS), and
(ii) a guide RNA that directs said endonuclease to at least one targeted locus in the gene encoding the immune checkpoint protein in the T-cell genome,

(c) expanding the genetically modified T-cells to generate at least 104 of the expanded genetically modified T-cells for cancer immunotherapy.